Future Research Directions To further clarify remaining uncertainty, future research should prioritize: Longer follow-up periods in large, active-comparator cohorts Mandatory histologic subtype linkage in registry studies International collaboration to increase power for rare outcomes like MTC Prospective registries in high-risk populations Transparent reporting of surveillance intensity and imaging utilization Final Conclusions After comprehensive review of mechanistic data, randomized trials, observational cohorts, pharmacovigilance analyses, and expert syntheses, the following conclusions are supported: There is no convincing human evidence that GLP-1 receptor agonists cause papillary, follicular, or Oncocytic (Hrthle cell) thyroid cancers The FDA boxed warning is appropriately narrow, reflecting rodent findings relevant to medullary thyroid carcinoma and MEN2 Apparent associations in some studies are plausibly explained by detection bias, confounding, and outcome misclassification Broad extrapolation of the warning to all thyroid cancers is not scientifically justified Evidence-based, subtype-specific counseling is essential to avoid unnecessary fear and ensure appropriate use of effective therapies This white paper is intended to serve as a durable reference for clinicians, patients, media professionals, and policymakers navigating a complex topic at the intersection of endocrinology, oncology, and public communication
For patients, recognizing that side effects vary in severity and that weight loss may plateau over time can foster more realistic expectations and better decision-making about whether to continue treatment
Thus, there is an urgent need for more non-pharmacological approaches for the early management of depression
Dynasty Clinic prioritize your safety with thorough consultations, medical oversight, and high quality, pharmaceutical grade peptides
169 YuanH.LiX.ZhangX.KangR.TangD
The 2022 JAMA Internal Medicine meta-analysis of 76 randomized trials reported an association between GLP-1 receptor agonist use and biliary disease broadly, with a relative risk of 1.55
